Literature DB >> 28520997

Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations.

David R Tribble1.   

Abstract

BACKGROUND: : Diarrhea is a frequent clinical syndrome affecting international travellers. Bacterial etiologic agents have a long history of emergent antimicrobial resistance against commonly used antibiotics. Current approaches applying first-line antimicrobial therapy are being challenged by increasingly resistant organisms. This review summarizes recent epidemiological and clinical evidence of antibiotic resistance among enteropathogens causing traveller's diarrhea and the subsequent impact on current treatment recommendations.
METHODS: : The PubMed database was systemically searched for articles related to antibiotic susceptibility and diarrheal pathogens.
RESULTS: : Antibiotic resistance related to travellers' diarrhea has increased in recent years. Most notably, fluoroquinolone resistance has expanded from the Campylobacter -associated cases well documented in Southeast Asia in the 1990s to widespread occurrence, as well as increases among other common bacterial enteropathogens including, enterotoxigenic and enteroaggregative Escherichia coli , Shigella and non-typhoidal Salmonella . Multidrug resistance among enteropathogenic Enterobacteriacae and Campylobacter species create further challenges with the selection of empiric therapy. Treatment failures requiring early use of alternative agents, as well as delayed recovery comparable to placebo rates emphasize the impact of antimicrobial resistance on effective treatment.
CONCLUSIONS: : Although there are limitations in the available data, the increasing antibiotic resistance and adverse impact on clinical outcome require continued surveillance and reconsideration of practice guidelines. Published by Oxford University Press 2017. This work is written by a US Government employee and is in the public domain in the US.

Entities:  

Keywords:  Campylobacter; Enterotoxigenic E. coli; Salmonella; Shigella; Traveller’s diarrhea; antimicrobial resistance

Mesh:

Substances:

Year:  2017        PMID: 28520997      PMCID: PMC5731445          DOI: 10.1093/jtm/taw090

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  54 in total

1.  Epidemiology and outcome of Shigella, Salmonella and Campylobacter infections in travellers returning from the tropics with fever and diarrhoea.

Authors:  E Bottieau; J Clerinx; E Vlieghe; M Van Esbroeck; J Jacobs; A Van Gompel; J Van Den Ende
Journal:  Acta Clin Belg       Date:  2011 May-Jun       Impact factor: 1.264

Review 2.  Post-infectious sequelae of travelers' diarrhea.

Authors:  Bradley A Connor; Mark S Riddle
Journal:  J Travel Med       Date:  2013-07-09       Impact factor: 8.490

Review 3.  Expert review of the evidence base for self-therapy of travelers' diarrhea.

Authors:  Herbert L DuPont; Charles D Ericsson; Michael J G Farthing; Sherwood Gorbach; Larry K Pickering; Lars Rombo; Robert Steffen; Thomas Weinke
Journal:  J Travel Med       Date:  2009-03-19       Impact factor: 8.490

4.  Epidemiology and antimicrobial resistance of international travel-associated Campylobacter infections in the United States, 2005-2011.

Authors:  Emily E Ricotta; Amanda Palmer; Katie Wymore; Paula Clogher; Nadine Oosmanally; Trisha Robinson; Sarah Lathrop; Jillian Karr; Julie Hatch; John Dunn; Patricia Ryan; David Blythe
Journal:  Am J Public Health       Date:  2014-05-15       Impact factor: 9.308

5.  Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years.

Authors:  C W Hoge; J M Gambel; A Srijan; C Pitarangsi; P Echeverria
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

6.  Shigellosis in Subjects with Traveler's Diarrhea Versus Domestically Acquired Diarrhea: Implications for Antimicrobial Therapy and Human Immunodeficiency Virus Surveillance.

Authors:  Carlos Toro; Ana Arroyo; Ana Sarria; Nuria Iglesias; Ana Enríquez; Margarita Baquero; Concepción Ladrón de Guevara
Journal:  Am J Trop Med Hyg       Date:  2015-07-20       Impact factor: 2.345

Review 7.  Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis.

Authors:  Mark S Riddle; Sarah Arnold; David R Tribble
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

8.  Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006.

Authors:  Erika R Vlieghe; Jan A Jacobs; Marjan Van Esbroeck; Olivier Koole; Alfons Van Gompel
Journal:  J Travel Med       Date:  2008 Nov-Dec       Impact factor: 8.490

9.  Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant Shigella Strains--Victoria, Australia.

Authors:  Courtney R Lane; Brett Sutton; Mary Valcanis; Martyn Kirk; Cathryn Walker; Karin Lalor; Nicola Stephens
Journal:  Clin Infect Dis       Date:  2015-12-17       Impact factor: 9.079

Review 10.  Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.

Authors:  B Gu; M Zhou; X Ke; S Pan; Y Cao; Y Huang; L Zhuang; G Liu; M Tong
Journal:  Epidemiol Infect       Date:  2015-01-02       Impact factor: 4.434

View more
  19 in total

Review 1.  Enterotoxigenic Escherichia coli Infections.

Authors:  James M Fleckenstein; F Matthew Kuhlmann
Journal:  Curr Infect Dis Rep       Date:  2019-03-04       Impact factor: 3.725

2.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

3.  Travelers' Diarrhea in Thailand: A Quantitative Analysis Using TaqMan® Array Card.

Authors:  Paphavee Lertsethtakarn; Sasikorn Silapong; Pimmada Sakpaisal; Oralak Serichantalergs; Nattaya Ruamsap; Woradee Lurchachaiwong; Sinn Anuras; James A Platts-Mills; Jie Liu; Eric R Houpt; Ladaporn Bodhidatta; Brett E Swierczewski; Carl J Mason
Journal:  Clin Infect Dis       Date:  2018-06-18       Impact factor: 9.079

4.  Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.

Authors:  Hyesuk Seo; Carolina Garcia; Xiaosai Ruan; Qiangde Duan; David A Sack; Weiping Zhang
Journal:  Infect Immun       Date:  2021-06-16       Impact factor: 3.441

5.  Cross-Protective Shigella Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain.

Authors:  Min Jung Kim; Young-Hye Moon; Heejoo Kim; Semi Rho; Young Kee Shin; Manki Song; Richard Walker; Cecil Czerkinsky; Dong Wook Kim; Jae-Ouk Kim
Journal:  Front Microbiol       Date:  2018-10-31       Impact factor: 5.640

6.  Extended-spectrum β-lactamase prevalence and virulence factor characterization of enterotoxigenic Escherichia coli responsible for acute diarrhea in Nepal from 2001 to 2016.

Authors:  Katie R Margulieux; Apichai Srijan; Sirigade Ruekit; Panida Nobthai; Kamonporn Poramathikul; Prativa Pandey; Oralak Serichantalergs; Sanjaya K Shrestha; Ladaporn Bodhidatta; Brett E Swierczewski
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-20       Impact factor: 4.887

7.  In vitro activity of fosfomycin against Campylobacter isolates from poultry and wild birds.

Authors:  Bai Wei; Min Kang
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

8.  Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay.

Authors:  Moon H Nahm; Jigui Yu; Hailey P Weerts; Heather Wenzel; Chitradevi S Tamilselvi; Lakshmi Chandrasekaran; Marcela F Pasetti; Sachin Mani; Robert W Kaminski
Journal:  mSphere       Date:  2018-06-13       Impact factor: 4.389

9.  Genome-wide screens reveal Escherichia coli genes required for growth of T1-like phage LL5 and V5-like phage LL12.

Authors:  Denish Piya; Lauren Lessor; Brian Koehler; Ashley Stonecipher; Jesse Cahill; Jason J Gill
Journal:  Sci Rep       Date:  2020-05-15       Impact factor: 4.379

10.  U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.

Authors:  Lorena M Coria; Franco L Martinez; Laura A Bruno; Karina A Pasquevich; Juliana Cassataro
Journal:  Vaccine       Date:  2020-06-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.